Table 2.
Demographic data for patients who reconsented for extended follow-up (n = 90)
| Baseline data | PVI (n = 49) | CTI ablation (n = 42) | P-value |
|---|---|---|---|
| Age (years), mean ± SD | 65.1 ± 9.4 | 68.4 ± 9.2 | 0.104 |
| Male sex, n (%) | 43 (87.8) | 35 (83.3) | 0.565 |
| BMI (kg/m2), mean (SD) | 29.5 ± 4.4 | 27.8 ± 4.0 | 0.059 |
| Smoking status, n (%) | 0.127 | ||
| Current | 1 (2.1) | 5 (12.2) | |
| Past | 25 (52.1) | 16 (39.0) | |
| Never | 22 (45.8) | 20 (48.8) | |
| Alcohol score*, mean ± SD | 4.5 ± 3.2 | 4.4 ± 3.0 | 0.855 |
| Months since flutter diagnosis, median (IQR) | 6 (3–12) | 10.5 (3–20) | 0.210 |
| Previous cardioversion, n (%) | 25 (51.0) | 23 (54.8) | 0.834 |
| LA diameter (cm), mean ± SD | 4.0 ± 0.6 | 4.2 ± 0.6 | 0.183 |
| LVEF (%), mean ± SD | 55.5 ± 7.8 | 55.5 ± 9.9 | 0.975 |
| Comorbidities, n (%) | |||
| Hypertension | 11 (22.4) | 13 (31.0) | 0.475 |
| Diabetes | 7 (14.3) | 1 (2.4) | 0.065 |
| Prior ACS | 4 (8.2) | 1 (2.4) | 0.369 |
| Prior PCI | 4 (8.2) | 2 (4.8) | 0.683 |
| Prior CABG | 4 (8.2) | - | 0.121 |
| Heart failure | 1 (2.0) | 2 (4.8) | 0.593 |
| Prior stroke, TIA, or systemic embolism | 4 (8.2) | 4 (9.5) | > 0.999 |
| CHA2DS2Vasc score, mean ± SD | 1.4 ± 1.4 | 1.7 ± 1.3 | 0.194 |
| Medication, n (%) | |||
| Beta blocker | 33 (67.3) | 32 (76.2) | 0.486 |
| Calcium channel blocker | 8 (16.3) | 3 (7.1) | 0.213 |
| ACE inhibitor/ARB | 9 (18.4) | 10 (23.8) | 0.609 |
| Class I antiarrhythmic | 3 (6.1) | 1 (2.4) | 0.621 |
| Class III antiarrhythmic | 2 (4.1) | 3 (7.1) | 0.659 |
| Digoxin | 2 (4.1) | 3 (7.1) | 0.659 |
Alcohol score—AUDIT-C questionnaire ranging from 0 (lowest risk) to 12 (highest risk)
ACE angiotensin-converting enzyme, ACS acute coronary syndrome, ARB angiotensin 2 receptor blocker, BMI body mass index, CABG coronary artery bypass graft, IQR interquartile range, LA left atrium, LV left ventricle, PCI percutaneous coronary intervention, SD standard deviation, TIA transient ischaemic attack